Mireia Margeli Vila

Universitat Autònoma de Barcelona (UAB)

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (7)

Montserrat Muñoz Mateu

Professora associada

University of Barcelona

SPAIN

View details

Eva Riveira Muñoz

AIDS Research Institute Irsicaixa

SPAIN

View details

Jordi Canes

Scientific Manager Head

SPAIN

View details

Juan Rafael de la Haba Rodríguez

Profesor Titular

Universidad de Córdoba

SPAIN

View details

Miguel Martin

Universidad Complutense de Madrid

SPAIN

View details

Eva M. Ciruelos-Gil

Universidad Complutense de Madrid

SPAIN

View details

Gustavo Tapia Melendo

University of Barcelona

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mireia Margeli Vila

Research Interests

Explore related searches

Contact this professor

Articles (10)

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer

Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer

Collaborators (7)

Montserrat Muñoz Mateu

Eva Riveira Muñoz

Jordi Canes

Juan Rafael de la Haba Rodríguez

Miguel Martin

Eva M. Ciruelos-Gil

Gustavo Tapia Melendo

Make your next move.